25 However, improvement in local control, the primary endpoint, did not reach statistical significance. 25 This contrasts with the more optimistic finding of the randomised phase III BCON (Bladder Carbogen Nicotinamide) trial ( NCT00033436 ) involving 333 patients with bladder cancer—differences in overall survival (OS), death risk and local relapse were in favour of carbogen/nicotinamide combined w
1
—
—